Abstract
On September 17, 2021, the FDA approved cabozantinib (Cabometyx; Exelixis, Inc.) for the treatment of adult and pediatric patients 12 years of age and......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
